- December 3, 2020
- Category: Biotechnology, Healthcare and LifeSciences
Global Cancer Vaccines Market Size study, by Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines), by Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Viral Vector & DNA Cancer Vaccines), by Indication (Cervical Cancer, Prostate Cancer, Others), by End-User (Pediatrics, Adults) and Regional Forecasts 2020-2027
Chapter 1. Executive Summary 1.1. Market Snapshot 1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion) 1.2.1. Cancer Vaccines Market, by Region, 2018-2027 (USD Billion) 1.2.2. Cancer Vaccines Market, by Type, 2018-2027 (USD Billion) 1.2.3. Cancer Vaccines Market, by Technology, 2018-2027 (USD Billion) 1.2.4. Cancer Vaccines Market, by Indication, 2018-2027 (USD Billion) 1.2.5. Cancer Vaccines Market, by End-User, 2018-2027 (USD Billion) 1.3. Key Trends 1.4. Estimation Methodology 1.5. Research Assumption Chapter 2. Global Cancer Vaccines Market Definition and Scope 2.1. Objective of the Study 2.2. Market Definition & Scope 2.2.1. Scope of the Study 2.2.2. Industry Evolution 2.3. Years Considered for the Study 2.4. Currency Conversion Rates Chapter 3. Global Cancer Vaccines Market Dynamics 3.1. Cancer Vaccines Market Impact Analysis (2018-2027) 3.1.1. Market Drivers 3.1.2. Market Challenges 3.1.3. Market Opportunities Chapter 4. Global Cancer Vaccines Market: Industry Analysis 4.1. Porter’s 5 Force Model 4.1.1. Bargaining Power of Suppliers 4.1.2. Bargaining Power of Buyers 4.1.3. Threat of New Entrants 4.1.4. Threat of Substitutes 4.1.5. Competitive Rivalry 4.1.6. Futuristic Approach to Porter’s 5 Force Model (2017-2027) 4.2. PEST Analysis 4.2.1. Political 4.2.2. Economical 4.2.3. Social 4.2.4. Technological 4.3. Investment Adoption Model 4.4. Analyst Recommendation & Conclusion Chapter 5. Global Cancer Vaccines Market, by Type 5.1. Market Snapshot 5.2. Global Cancer Vaccines Market by Type, Performance - Potential Analysis 5.3. Global Cancer Vaccines Market Estimates & Forecasts by Type 2017-2027 (USD Billion) 5.4. Cancer Vaccines Market, Sub Segment Analysis 5.4.1. Preventive Cancer Vaccines 5.4.2. Therapeutic Cancer Vaccines Chapter 6. Global Cancer Vaccines Market, by Technology 6.1. Market Snapshot 6.2. Global Cancer Vaccines Market by Technology, Performance - Potential Analysis 6.3. Global Cancer Vaccines Market Estimates & Forecasts by Technology 2017-2027 (USD Billion) 6.4. Cancer Vaccines Market, Sub Segment Analysis 6.4.1. Dendritic Cells (DC) Cancer Vaccines 6.4.2. Recombinant Cancer Vaccines 6.4.3. Antigen/Adjuvant Cancer Vaccines 6.4.4. Viral Vector & DNA Cancer Vaccines Chapter 7. Global Cancer Vaccines Market, by Indication 7.1. Market Snapshot 7.2. Global Cancer Vaccines Market by Indication, Performance - Potential Analysis 7.3. Global Cancer Vaccines Market Estimates & Forecasts by Indication 2017-2027 (USD Billion) 7.4. Cancer Vaccines Market, Sub Segment Analysis 7.4.1. Cervical Cancer 7.4.2. Prostate Cancer 7.4.3. Others Chapter 8. Global Cancer Vaccines Market, by End-User 8.1. Market Snapshot 8.2. Global Cancer Vaccines Market by End-User - Potential Analysis 8.3. Global Cancer Vaccines Market Estimates & Forecasts by End-User 2017-2027 (USD Billion) 8.4. Cancer Vaccines Market, Sub Segment Analysis 8.4.1. Paediatrics 8.4.2. Adults Chapter 9. Global Cancer Vaccines Market, Regional Analysis 9.1. Cancer Vaccines Market, Regional Market Snapshot 9.2. North America Cancer Vaccines Market 9.2.1. U.S. Cancer Vaccines Market 22.214.171.124. Type breakdown estimates & forecasts, 2017-2027 126.96.36.199. Technology breakdown estimates & forecasts, 2017-2027 188.8.131.52. Indication breakdown estimates & forecasts, 2017-2027 184.108.40.206. End-User breakdown estimates & forecasts, 2017-2027 9.2.2. Canada Cancer Vaccines Market 9.3. Europe Cancer Vaccines Market Snapshot 9.3.1. U.K. Cancer Vaccines Market 9.3.2. Germany Cancer Vaccines Market 9.3.3. France Cancer Vaccines Market 9.3.4. Spain Cancer Vaccines Market 9.3.5. Italy Cancer Vaccines Market 9.3.6. Rest of Europe Cancer Vaccines Market 9.4. Asia-Pacific Cancer Vaccines Market Snapshot 9.4.1. China Cancer Vaccines Market 9.4.2. India Cancer Vaccines Market 9.4.3. Japan Cancer Vaccines Market 9.4.4. Australia Cancer Vaccines Market 9.4.5. South Korea Cancer Vaccines Market 9.4.6. Rest of Asia Pacific Cancer Vaccines Market 9.5. Latin America Cancer Vaccines Market Snapshot 9.5.1. Brazil Cancer Vaccines Market 9.5.2. Mexico Cancer Vaccines Market 9.6. Rest of The World Cancer Vaccines Market Chapter 10. Competitive Intelligence 10.1. Top Market Strategies 10.2. Company Profiles 10.2.1. Advaxis Inc. 10.2.1.1. Key Information 10.2.1.2. Overview 10.2.1.3. Financial (Subject to Data Availability) 10.2.1.4. Product Summary 10.2.1.5. Recent Developments 10.2.2. Amgen Inc. 10.2.3. Dynavax Technologies Corporation 10.2.4. Generex Biotechnology Corporation 10.2.5. GlaxoSmithKline plc (GSK) 10.2.6. Immunocellular Therapeutics, Ltd. 10.2.7. Merck & Co., Inc. 10.2.8. Sanpower Group Co. Ltd. 10.2.9. UbiVac, Inc. 10.2.10. Vaccinogen, Inc. Chapter 11. Research Process 11.1. Research Process 11.1.1. Data Mining 11.1.2. Analysis 11.1.3. Market Estimation 11.1.4. Validation 11.1.5. Publishing 11.2. Research Attributes 11.3. Research Assumption
Global Cancer Vaccines Market is valued at approximately USD 4.2 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 12.6% over the forecast period 2020-2027. Cancer vaccines are a form of immunotherapy which is considered as a biological response modifier. Usually, cancer treatment vaccines are distinct from the vaccines that work against bacteria and viruses. Cancer vaccines can stimulate the immune system of the patient’s body to fight against cancer cells. Rather than preventing disease, these vaccines are primarily focused to boost the immune systems to medicate a disease that already occurred in the patient’s body. The cancer vaccines are generally available in two types i.e. preventive cancer vaccines and therapeutic cancer vaccines. Preventive cancer vaccines are typically used to prevent cancer disease among healthy people, whereas therapeutic cancer vaccines are used to strengthen the immune response among patients to fight against the disease. An increase in the number of cancer patients, growing awareness among patients towards cancer therapy, and rising investment and government funding in the development of cancer vaccine are the few factors responsible for the CAGR of the market during the forecast period. According to the International Agency for Research on Cancer (IARC), around 18.1 million new cancer cases and 9.6 million cancer deaths were reported throughout the world in 2018. Also, the global prevalence of cancer is projected to grow to around 27.5 million new cancer cases and nearly 16.3 million cancer deaths by the year 2040. This, in turn, is likely to strengthen the demand for Cancer Vaccines, globally. However, the high development cost of vaccine and stringent government norms & policies on product approval are the few factors impeding the market growth over the forecast period of 2020-2027.
The regional analysis of the global Cancer Vaccines market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the favorable government support for the approval of cancer vaccines, along with the wide presence of market players in the region. Whereas Asia-Pacific is anticipated to exhibit the highest growth rate / CAGR over the forecast period 2020-2027. Factors such as the rise in prevalence of cancer and improving healthcare infrastructure in the developing nations, such as China and India, are the few factors creating a lucrative opportunity for the growth of the cancer vaccine market in the Asia-Pacific region.
Major market player included in this report are:
Dynavax Technologies Corporation
Generex Biotechnology Corporation
GlaxoSmithKline plc (GSK)
Immunocellular Therapeutics, Ltd.
Merck & Co., Inc.
Sanpower Group Co. Ltd.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
Preventive Cancer Vaccines
Therapeutic Cancer Vaccines
Dendritic Cells (DC) Cancer Vaccines
Recombinant Cancer Vaccines
Antigen/Adjuvant Cancer Vaccines
Viral Vector & DNA Cancer Vaccines
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2017, 2018
Base year – 2019
Forecast period – 2020 to 2027
Target Audience of the Global Cancer Vaccines Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Value-Added Resellers (VARs)
Third-party knowledge providers